	US 12,083,170 B2
	Prohemostatic proteins for the treatment of bleeding
Daniël Verhoef, Leiden (NL); Pieter H. Reitsma, Leiden (NL); and Mettine H. A. Bos, Leiden (NL)
Assigned to Academisch Ziekenhuis Leiden, Leiden (NL)
Filed by Academisch Ziekenhuis Leiden
Filed on May 31, 2022, as Appl. No. 17/829,180.
Application 17/829,180 is a continuation of application No. 16/719,866, filed on Dec. 18, 2019, granted, now 11,357,836.
Application 16/719,866 is a continuation of application No. 15/313,881, granted, now 10,537,618, issued on Jan. 21, 2020, previously published as PCT/NL2015/050377, filed on May 26, 2015.
Claims priority of application No. 14169895 (EP), filed on May 26, 2014.
Prior Publication US 2022/0288172 A1, Sep. 15, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/48 (2006.01); C07K 14/46 (2006.01); C12N 9/64 (2006.01)

CPC A61K 38/4846 (2013.01) [C07K 14/46 (2013.01); C12N 9/6432 (2013.01); C12Y 304/21006 (2013.01); C07K 2319/00 (2013.01)]

11 Claims

1. A recombinant protein comprising:

a coagulation factor Xa polypeptide having an alteration in a region of amino acid residues corresponding to the region of amino acid residues between His-311 and Asp-320 of SEQ ID NO: 1,

wherein the alteration is an insertion of from 1-20 amino acid residues.